pmid,pmcid,title,chunk_id,text,has_full_text
28111296,12693416,Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets.,28111296_0,alzheimer s disease ad is a well known cause of memory loss and dementia in elderly people all across the world it is pathophysiologically characterized by the extracellular deposition of amyloid beta a proteins and retention of intracellular neurofibrillary tangles nfts of hyperphosphorylated tau proteins several enzymes such as lipoxygenases acetylcholinesterases secretases glycogen synthase kinase caspases sirtuins have been reported to actively participate in the pathogenesis of ad due to the limited drug for the management of ad till now only memantine and four other acetylcholinesterase inhibitors there is an urgent need to find out the novel inhibitors that could specifically act against these enzymes or therapeutically important targets and barricade or decelerate ad progression in this current review we aim to unravel various enzymes and their potential inhibitors that could be exploited against ad pathogenesis we have also covered several other important miscellaneous targets which could be used as ad therapeutics,True
35114208,12631682,Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.,35114208_0,for the past several years dementia is one of the predominantly observed groups of symptoms in a geriatric population alzheimer s disease ad is a progressive memory related neurodegenerative disease for which the current food and drug administration approved therapeutics are only meant for a symptomatic management rather than targeting the root cause of ad these therapeutics belong to two classes acetylcholine esterase inhibitors and n methyl d aspartate antagonist furthermore to facilitate neuroprotective action in ad the drugs are majorly expected to reach the specific target area in the brain for the desired efficacy thus there is a huge requirement for drug discovery and development for facilitating the entry of drugs more in brain to exert a specific action the very first line of defense and the major limitation for the entry of drugs into the brain is the blood brain barrier followed by blood cerebrospinal fluid barrier more than a barrier these mainly act as selectively permeable membranes which allows entry of specific molecules into the brain furthermore specific enzymes result in the degradation of xenobiotics all these mechanisms pose as hurdles in the way of effective drug delivery in the brain thus novel techniques need to be harbored for the facilitation of the delivery of such drugs into the brain nanocarriers are advantageous for facilitating the specific targeted drug treatment in ad as nanomedicines are one of the novels and most useful approaches for ad thus the present review mainly focuses on understanding the advanced use of nanocarriers for targeted drug delivery in the management of ad,True
39062547,11274940,Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies.,39062547_0,microglia as resident macrophages in the central nervous system play a multifunctional role in the pathogenesis of alzheimer s disease ad their clustering around amyloid a deposits is a core pathological feature of ad recent advances in single cell rna sequencing scrna seq and single nucleus rna sequencing snrna seq have revealed dynamic changes in microglial phenotypes over time and across different brain regions during aging and ad progression as ad advances microglia primarily exhibit impaired phagocytosis of a and tau along with the release of pro inflammatory cytokines that damage synapses and neurons targeting microglia has emerged as a potential therapeutic approach for ad treatment strategies involving microglia can be broadly categorized into two aspects enhancing microglial function this involves augmenting their phagocytic ability against a and cellular debris and mitigating neuroinflammation strategies include inhibiting tnf signaling to reduce the neuroinflammatory response triggered by microglia clinical trials exploring microglia related approaches for ad treatment have garnered attention additionally natural products show promise in enhancing beneficial effects and suppressing inflammatory responses clarifying microglial dynamics understanding their roles and exploring novel therapeutic approaches will advance our fight against ad,True
32129117,12706182,Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation.,32129117_0,b introduction b despite the revolutionary progress in neurodegenerative disease research there is no cure for alzheimer s disease ad this is a chronic progressive neurodegenerative disease affecting aged people and is associated with chronic neuroinflammation and amyloid beta a deposition in the brain parenchyma microglia the resident myeloid cells in the central nervous system are critically involved in the pathogenesis of ad and have emerged as a potential therapeutic target for treating or preventing ad the failure of microglia to keep up with persistent amyloid beta development along with secretion of inflammatory cytokines is detrimental to neurons and favors a accumulation b areas covered b this review illuminates the latest research that is focused on molecules and their intracellular targets that promote microglial phagocytosis and or its polarization to an anti inflammatory state b expert opinion b a robust inflammatory response of microglia is not necessary to improve their efficiency of a clearance the challenge is to master inflammatory anti inflammatory phenotypes depending on the stage of ad and to maintain efficient responses to remove a therefore promoting microglia phagocytosis without a persistent excessive inflammatory response could be a potential therapeutic strategy,True
39272998,11394242,Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease.,39272998_0,there is an urgent need for effective disease modifying therapeutic interventions for alzheimer s disease ad the most prevalent cause of dementia with a profound socioeconomic burden most clinical trials targeting the classical hallmarks of this disease amyloid plaques and neurofibrillary tangles failed showed discrete clinical effects or were accompanied by concerning side effects there has been an ongoing search for novel therapeutic targets neuroinflammation now widely recognized as a hallmark of all neurodegenerative diseases has been proven to be a major contributor to ad pathology here we summarize the role of neuroinflammation in the pathogenesis and progression of ad and discuss potential targets such as microglia trem the complement system inflammasomes and cytosolic dna sensors we also present an overview of ongoing studies targeting specific innate immune system components highlighting the progress in this field of drug research while bringing attention to the delicate nature of innate immune modulations in ad,True
27660215,12375993,"Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.",27660215_0,given the importance of microglia to inflammatory phagocytic and synaptic modulatory processes their function is vital in physiological and pathological brain the impairment of microglia in alzheimer s disease has been demonstrated on genetic epigenetic transcriptional and functional levels using unbiased systems level approaches recent studies have highlighted the immense phenotypic diversity of microglia including the ability to adopt distinct and dynamic phenotypes in ageing and disease we review the origins and functions of healthy microglia and the established and emerging models and techniques available for their study furthermore we highlight recent advances on the role heterogeneity and dysfunction of microglia in alzheimer s disease and discuss the potential for therapeutic interventions targeting microglia microglia selective molecular fingerprints will guide detailed functional analysis of microglial subsets and may aid in the development of therapies specifically targeting microglia,True
37424345,,Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.,37424345_0,the delivery of drugs to the brain is quite challenging in the treatment of the central nervous system cns diseases due to the blood brain barrier and the blood cerebrospinal fluid barrier however significant developments in nanomaterials employed by nanoparticle drug delivery systems have substantial potential to cross or bypass these barriers leading to enhanced therapeutic efficacies advances in nanoplatform nanosystems based on lipids polymers and inorganic materials have been extensively studied and applied in treating alzheimer s and parkinson s diseases in this review various types of brain drug delivery nanocarriers are classified summarized and their potential as drug delivery systems in alzheimer s and parkinson s diseases is discussed finally challenges facing the clinical translation of nanoparticles from bench to bedside are highlighted,False
39271059,12609898,Amyloid-β-targeting immunotherapies for Alzheimer's disease.,39271059_0,recent advances in clinical passive immunotherapy have provided compelling evidence that eliminating amyloid a slows cognitive decline in alzheimer s disease ad however the modest benefits and side effects observed in clinical trials indicate that current immunotherapy therapy is not a panacea highlighting the need for a deeper understanding of ad mechanisms and the significance of early intervention through optimized immunotherapy or immunoprevention this review focuses on the centrality of a pathology in ad and summarizes recent clinical progress in passive and active immunotherapies targeting a discussing their lessons and failures to inform future anti a biotherapeutics design various delivery strategies to optimize a targeting immunotherapies are outlined highlighting their benefits and drawbacks in overcoming challenges such as poor stability and limited tissue accessibility of anti a biotherapeutics additionally the perspectives and challenges of immunotherapy and immunoprevention targeting a are concluded in the end aiming to guide the development of next generation anti a immunotherapeutic agents towards improved efficacy and safety,True
40810239,12340599,"Understanding the role of microglia in Alzheimer's disease: insights into mechanisms, acupuncture, and potential therapeutic targets.",40810239_0,microglia mg are immune effector cells in the central nervous system cns and play a pivotal role in the pathogenesis of various cns diseases alzheimer s disease ad is defined as a severe chronic degenerative neurological disease in humans the amyloid cascade hypothesis is a hypothesis on the pathogenesis of ad that suggests that abnormal extracellular aggregation of amyloid a peptides is the main cause of the disease although this hypothesis has been found to be convincing a growing body of evidence suggests that it does not fully explain the pathogenesis of ad neuroinflammation is a crucial element in the pathogenesis of ad as evidenced by elevated levels of inflammatory markers and the identification of ad risk genes associated with innate immune function this paper will first summarize the impact of microglia mediated neuroinflammation on ad exploring the phenotypic changes that follow microglia activation secondly the interactions between microglia a microtubule associated protein apolipoprotein e and neurons are thoroughly investigated with particular focus on the interactive mechanisms furthermore the recent progress and prospects of microglia as a diagnostic and therapeutic target for ad are analysed a review of the literature on the mechanisms regulating mg for ad at home and abroad revealed that acupuncture modulation of microglia could help to delay the progression of ad this was followed by an extensive discussion of the clinical possibilities and scientific validity of acupuncture treatment for ad with the aim of providing new insights for acupuncture modulation of mg targeting for the treatment of ad,False
39562009,11734340,The emerging field of non-invasive brain stimulation in Alzheimer's disease.,39562009_0,treating cognitive impairment is a holy grail of modern clinical neuroscience in the past few years non invasive brain stimulation is increasingly emerging as a therapeutic approach to ameliorate performance in patients with cognitive impairment and as an augmentation approach in persons whose cognitive performance is within normal limits in patients with alzheimer s disease better understanding of brain connectivity and function has allowed for the development of different non invasive brain stimulation protocols recent studies have shown that transcranial stimulation methods enhancing brain plasticity with several modalities have beneficial effects on cognitive functions amelioration has been shown in preclinical studies on behaviour of transgenic mouse models for alzheimer s pathology and in clinical studies with variable severity of cognitive impairment while the field is still grappling with issues related to the standardization of target population frequency intensity treatment duration and stimulated region positive outcomes have been reported on cognitive functions and on markers of brain pathology here we review the most encouraging protocols based on repetitive transcranial magnetic stimulation transcranial direct current stimulation transcranial alternating current stimulation visual auditory stimulation photobiomodulation and transcranial focused ultrasound which have demonstrated efficacy to enhance cognitive functions or slow cognitive decline in patients with alzheimer s disease beneficial non invasive brain stimulation effects on cognitive functions are associated with the modulation of specific brain networks the most promising results have been obtained targeting key hubs of higher level cognitive networks such as the frontal parietal network and the default mode network the personalization of stimulation parameters according to individual brain features sheds new light on optimizing non invasive brain stimulation protocols for future applications,True
38424435,12289688,The Unveiling of Therapeutic Targets for Alzheimer's Disease: An Integrative Review.,38424435_0,alzheimer s disease ad is characterized by a complex pathological landscape necessitating a comprehensive treatment approach this concise review paper delves into the idea of addressing multiple mechanisms in ad summarizing the latest research findings on pathogenesis risk factors diagnostics and therapeutic strategies the etiology of ad is multifaceted involving genetic environmental and lifestyle factors the primary feature is the accumulation of amyloid beta and tau proteins leading to neuroinflammation synaptic dysfunction oxidative stress and neuronal loss conventional single target therapies have shown limited effectiveness prompting a shift toward simultaneously addressing multiple disease related processes recent advancements in ad research underscore the potential of multifaceted therapies this review explores strategies targeting both tau aggregation and amyloid beta along with interventions to alleviate neuroinflammation enhance synaptic function and reduce oxidative stress in conclusion the review emphasizes the growing importance of addressing various pathways in ad treatment a holistic approach that targets different aspects of the disease holds promise for developing effective treatments and improving the quality of life for alzheimer s patients and their caregivers,True
39755304,,Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study.,39755304_0,certain peripheral proteins are believed to be involved in the development of alzheimer s disease ad but the roles of other new protein biomarkers are still unclear current treatments aim to manage symptoms but they are not effective in stopping the progression of the disease new drug targets are needed to prevent alzheimer s disease we used mendelian randomization mr to study drug targets for alzheimer s disease we analyzed data from the european alzheimer s and dementia biobank consortium and replicated our findings in gwas data from igap and finngen cohorts we identified genetic instruments for plasma and cerebrospinal fluid csf proteins and conducted sensitivity analyses using various methods additionally a comparison and analysis of protein protein interactions ppi were conducted to identify potential causal proteins the implications of these findings were further explored through an examination of existing ad drugs and their respective targets through mr analysis protein ad pairs were identified as statistically significant at the bonferroni level p sup sup the specific findings indicate that elevated levels of plasma cathepsin h ctsh or ci p sup sup plasma signal regulatory protein alpha sirpa or ci p sup sup plasma tmem b or ci p sup sup and csf bone sialoprotein bsp or ci p sup sup csf interleukin il or ci p sup sup csf immunoglobulin like transcript ilt or ci p sup sup are associated with an increased risk of ad while increased levels of plasma progranulin gene grn or ci p sup sup plasma triggering receptor expressed on myeloid cells trem or ci p sup sup plasma sialic acid bind immunoglobulin like lectins siglec or ci p sup sup and csf siglec or ci p sup sup are associated with a decreased risk of ad bayesian colocalization found that the above protein related genes shared the same mutation as ad increased levels of plasma ctsh sirpa tmem b csf bsp csf il and csf ilt have been found to be correlated with an elevated risk of ad whereas elevated levels of plasma grn trem siglec and csf siglec are associated with a decreased risk of developing ad further investigation through clinical trials is needed,False
12369937,3085892,Amyloid forming proteases: therapeutic targets for Alzheimer's disease.,12369937_0,alzheimer s disease is an age related neurodegenerative disease which causes global loss of cognitive function drug treatment for alzheimer s disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression rational drug design for the treatment of alzheimer s disease now seems possible as a result of major advances in medical research in this area knowledge of the etiology of alzheimer s disease is rapidly being understood this information has uncovered relevant and novel targets for treatment at the center of the etiological progression of this disease is beta amyloid a substantial body of evidence strongly suggests that this small protein is critical to the development of alzheimer s disease the beta amyloid protein is generated by two different proteolytic cleavages recently the proteases responsible for producing the beta amyloid protein have been identified the proteases represent viable targets for therapeutic intervention against alzheimer s disease in this review we describe the biological characteristics of the beta amyloid forming proteases in the context of pharmaceutical development,False
38981028,11425895,Blood Brain Barrier-Crossing Delivery of Felodipine Nanodrug Ameliorates Anxiety-Like Behavior and Cognitive Impairment in Alzheimer's Disease.,38981028_0,alzheimer s disease ad is the most common age related neurodegenerative disorder leading to cognitive decline excessive cytosolic calcium ca sup sup accumulation plays a critical role in the pathogenesis of ad since it activates the nod like receptor family pyrin domain containing nlrp switches the endoplasmic reticulum er unfolded protein response upr toward proapoptotic signaling and promotes a seeding herein a liposomal nanodrug felodipine lnd is developed incorporating a calcium channel antagonist felodipine for alzheimer s disease treatment through a low intensity pulse ultrasound lipus irradiation assisted blood brain barrier bbb crossing drug delivery the multifunctional felodipine lnd is effectively delivered to diseased brain through applying a lipus irradiation to the skull which resulted in a series of positive effects against ad markedly the nanodrug treatment switched the er upr toward antioxidant signaling prevented the surface translocation of er calreticulin calr in microglia and inhibited the nlrp activation and a seeding in addition it promoted the degradation of damaged mitochondria via mitophagy thereby inhibiting the neuronal apoptosis therefore the anxiety like behavior and cognitive impairment of xfad mice with ad is significantly ameliorated which manifested the potential of lipus assisted bbb crossing delivery of felodipine lnd to serve as a paradigm for ad therapy based on the well recognized clinically available felodipine,True
35821145,9277852,MicroRNA-22-3p ameliorates Alzheimer's disease by targeting SOX9 through the NF-κB signaling pathway in the hippocampus.,35821145_0,studies have suggested that many down regulated mirnas identified in the brain tissue or serum of alzheimer s disease ad patients were involved in the formation of senile plaques and neurofibrillary tangles specifically our previous study revealed that microrna p mir p was significantly down regulated in ad patients however the molecular mechanism underlying the down regulation of mir p has not been comprehensively investigated the ameliorating effect of mir p on apoptosis of the a treated ht cells was detected by tunel staining flow cytometry and western blotting the cognition of mice with stereotaxic injection of agomir or antagomir of mir p was assessed by morris water maze test pathological changes in the mouse hippocampus were analyzed using hematoxylin and eosin he staining nissl staining and immunohistochemistry proteomics analysis was performed to identify the targets of mir p which were further validated using dual luciferase reporter analysis and western blotting analysis the mir p played an important role in ameliorating apoptosis in the a treated ht cells increased levels of mir p in the mouse hippocampus improved the cognition in mice although the mir p did not cause the decrease of neuronal loss in the hippocampus it reduced the a deposition proteomics analysis revealed sox protein as the target of mir p which was verified by the luciferase reporter experiments our study showed that mir p could improve apoptosis and reduce a deposition by acting on sox through the nf b signaling pathway to improve the cognition in ad mice we concluded that mir p ameliorated ad by targeting sox through the nf b signaling pathway in the hippocampus,True
37452321,10349496,Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation.,37452321_0,alzheimer s disease ad contributes to most cases of dementia its prominent neuropathological features are the extracellular neuritic plaques and intercellular neurofibrillary tangles composed of aggregated amyloid a and hyperphosphorylated tau protein respectively in the past few decades disease modifying therapy targeting a has been the focus of ad drug development even though it is encouraging that two of these drugs have recently received accelerated us food and drug administration approval for ad treatment their efficacy or long term safety is controversial tau has received increasing attention as a potential therapeutic target since evidence indicates that tau pathology is more associated with cognitive dysfunction moreover inflammation especially neuroinflammation accompanies ad pathological processes and is also linked to cognitive deficits accumulating evidence indicates that inflammation has a complex and tight interplay with tau pathology here we review recent evidence on the interaction between tau pathology focusing on tau post translational modification and dissemination and neuroinflammatory responses including glial cell activation and inflammatory signaling pathways then we summarize the latest clinical trials targeting tau and neuroinflammation sustained and increased inflammatory responses in glial cells and neurons are pivotal cellular drivers and regulators of the exacerbation of tau pathology which further contributes to its worsening by aggravating inflammatory responses unraveling the precise mechanisms underlying the relationship between tau pathology and neuroinflammation will provide new insights into the discovery and clinical translation of therapeutic targets for ad and other tau related diseases tauopathies targeting multiple pathologies and precision therapy strategies will be the crucial direction for developing drugs for ad and other tauopathies,True
28252521,7932850,Alzheimer's disease pathology and the unfolded protein response: prospective pathways and therapeutic targets.,28252521_0,many vital interdependent cellular functions including proteostasis lipogenesis and ca homeostasis are executed by the endoplasmic reticulum er exogenous insults can impair er performance this must be rapidly corrected or cell death will ensue protective adaptations can boost the functional capacity of the er and form the basis of the unfolded protein response upr activated in response to the accumulation of misfolded proteins the upr can halt protein translation while increasing protein handling chaperones and the degradation of erroneous proteins through a conserved three tier molecular cascade however prolonged activation of the upr can result in the maladaptation of the system resulting in the activation of inflammatory and apoptotic effectors recently upr and its involvement in neurodegenerative disease has attracted much interest and numerous potentially drugable points of crosstalk are now emerging here we summarize the functions of the er and upr and highlight evidence for its potential role in the pathogenesis of alzheimer s disease before discussing several key targets with therapeutic potential,False
38777251,12733005,Pericytes in Alzheimer's disease: Key players and therapeutic targets.,38777251_0,alzheimer s disease ad is a devastating neurodegenerative disorder that leads to progressive cognitive decline and neuropathological changes pericytes which are vessel mural cells on the basement membrane of capillaries play a crucial role in regulating cerebrovascular functions and maintaining neurovascular unit integrity emerging research substantiates the involvement of pericytes in ad this review provides a comprehensive overview of pericytes including their structure origin and markers and various functions within the central nervous system emphatically the review explores the intricate mechanisms through which pericytes contribute to ad including their interactions with amyloid beta and apolipoprotein e as well as various signaling pathways the review also highlights potential for targeted pericyte therapy for ad with a focus on stem cell therapy and drug treatments future research directions include the classification of pericyte subtypes studies related to aging and the role of pericytes in exosome related mechanisms in ad pathology in conclusion this review consolidates current knowledge on the pivotal roles of pericytes in ad and their potential as therapeutic targets providing valuable insights for future research and clinical interventions aimed at addressing the impact of ad on patients lives,True
32814524,11678002,"Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches.",32814524_0,we describe herein the therapeutic targets involved in alzheimer s disease as well as the available drugs and their synthetic routes bioactive compounds under development are also exploited to illustrate some recent research advances on the medicinal chemistry of alzheimer s disease including structure activity relationships for some targets the importance of multi target approaches including some examples from our research projects guides new perspectives in search of more effective drug candidates this review comprises the period between and early,True
26813123,,Alzheimer's disease: Targeting the Cholinergic System.,26813123_0,acetylcholine ach has a crucial role in the peripheral and central nervous systems the enzyme choline acetyltransferase chat is responsible for synthesizing ach from acetyl coa and choline in the cytoplasm and the vesicular acetylcholine transporter vacht uptakes the neurotransmitter into synaptic vesicles following depolarization ach undergoes exocytosis reaching the synaptic cleft where it can bind its receptors including muscarinic and nicotinic receptors ach present at the synaptic cleft is promptly hydrolyzed by the enzyme acetylcholinesterase ache forming acetate and choline which is recycled into the presynaptic nerve terminal by the high affinity choline transporter cht cholinergic neurons located in the basal forebrain including the neurons that form the nucleus basalis of meynert are severely lost in alzheimer s disease ad ad is the most ordinary cause of dementia affecting million people worldwide the hallmarks of the disease are the accumulation of neurofibrillary tangles and amyloid plaques however there is no real correlation between levels of cortical plaques and ad related cognitive impairment nevertheless synaptic loss is the principal correlate of disease progression and loss of cholinergic neurons contributes to memory and attention deficits thus drugs that act on the cholinergic system represent a promising option to treat ad patients,False
21697951,3168999,New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc.,21697951_0,the molecular determinants of alzheimer s ad disease are still not completely known however in the past two decades a large body of evidence has indicated that an important contributing factor for the disease is the development of an unbalanced homeostasis of two signaling cations calcium ca and zinc zn both ions serve a critical role in the physiological functioning of the central nervous system but their brain deregulation promotes amyloid dysmetabolism as well as tau phosphorylation ad is also characterized by an altered glutamatergic activation and glutamate can promote both ca and zn dyshomeostasis the two cations can operate synergistically to promote the generation of free radicals that further intracellular ca and zn rises and set the stage for a self perpetuating harmful loop these phenomena can be the initial steps in the pathogenic cascade leading to ad therefore therapeutic interventions aiming at preventing ca and zn dyshomeostasis may offer a great opportunity for disease modifying strategies,False
27163828,11872870,MicroRNAs as Therapeutic Targets for Alzheimer's Disease.,27163828_0,alzheimer s disease ad is the most common cause of dementia in the elderly with increasing longevity and the absence of a cure ad has become not only a major health problem but also a heavy social and economic burden worldwide given this public health challenge and that the current approved therapy for ad is limited to symptomatic treatment i e cholinesterase inhibitors and nmda receptor antagonists exploration of new molecular pathways as novel therapeutic targets remains an attractive option for disease modifying drug development micrornas mirnas are short non coding rna that control gene expression at the post translational level by inhibiting translation of specific mrnas or degrading them dysregulation of several mirnas has been described in ad brains interestingly their molecular targets are pathways that are well established functional players in the onset and development of ad pathogenesis today several molecular tools have been developed to modulate mirna levels in vitro and in vivo these scientific advancements are affording us for the first time with the real possibility of targeting in vivo these dysregulated mirnas as a novel therapeutic approach against ad,False
28490260,12664551,Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.,28490260_0,the number of people with dementia including alzheimer s disease is growing as a result of an ageing global population treatments available for ad only alleviate the symptoms of the disease and are effective in some people with ad for a limited time there is no disease modifying treatment available and despite research efforts the underlying mechanisms of ad and optimal treatment targets have not been fully elucidated amyloid and tau are key pathological markers of ad with ongoing trials targeting both however there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease which are now being investigated areas covered this review summarizes current treatment approaches for ad and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline this includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies the studies included in this review have been obtained from searches of pubmed and clinical trials databases expert commentary there is a renewed energy in identifying better treatments for behavioural symptoms of ad using both novel drugs and repositioning existing drugs lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in ad,False
29562523,12833968,Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease.,29562523_0,the amyloid cascade hypothesis has been dominating drug discovery for alzheimer s disease ad for the last two decades the failure of the development of effective drugs for slowing down or reversing the progression of ad warrants the ad field to consider out of the box thinking and therapeutic approaches we propose the multifactorial hypothesis of ad emphasizing that ad is caused by multiple etiological factors which may result in common brain pathology and functional consequences through several separate but integrated molecular pathways more than one etiological factor and mechanistic pathway may be involved in a single individual with sporadic ad and different individuals may have different etiological factors involving different mechanisms pathways we urge the recognition of the multifactorial nature of ad and the paradigm shift of ad drug development from a single target to multiple targets either with the multitarget directed ligands approach or the cocktail therapy approach we believe that patient stratification and the use of the precision medicine model will also benefit ad drug discovery,True
39122455,12221416,Broadening Horizons: Exploring the Cathepsin Family as Therapeutic Targets for Alzheimer's Disease.,39122455_0,alzheimer s disease ad is an intricate neurodegenerative disorder characterized by the accumulation of misfolded proteins including beta amyloid a and tau leading to cognitive decline despite decades of research the precise mechanisms underlying its onset and progression remain elusive cathepsins are a family of lysosomal enzymes that play vital roles in cellular processes including protein degradation and regulation of immune responses emerging evidence suggests that cathepsins may be involved in ad pathogenesis cathepsins can influence the activation of microglia and astrocytes the resident immune cells in the brain however cathepsin dysfunction may lead to the accumulation of misfolded proteins notably a and tau in addition dysregulated cathepsin activity may induce an exaggerated immune response promoting chronic inflammation and neuronal dysfunction in patients with ad by unraveling the classification functions and roles of cathepsins in ad s pathogenesis this review sheds light on their intricate involvement in this devastating disease targeting cathepsin activity could be a promising and novel approach for mitigating the pathological processes that contribute to ad providing new avenues for its treatment and prevention,True
33983096,12820278,New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease.,33983096_0,alzheimer s disease ad is the most common neurodegenerative disease worldwide and its incidence is increasing due to the ageing population currently the main limitations of ad treatment are low blood brain barrier permeability severe off target of drugs and immune abnormality in this review four hypotheses for alzheimer s pathogenesis and three challenges for alzheimer s drug delivery are discussed in addition this article summarises the different strategies of brain targeting nano drug delivery systems nddss developed in the last years these strategies include receptor mediated transferrin receptor low density lipoprotein receptor related protein lactoferrin receptor etc adsorption mediated cationic alkaline polypeptide cell penetrating peptides etc and transporter mediated p gp glut etc moreover it provides insights into novel strategies used in ad such as exosomes virus like particles and cell membrane coating particles hence this review will help researchers to understand the current progress in the field of nddss for the central nervous system and find new directions for ad therapy highlightscharacteristics and challenges based on the pathogenesis of ad were discussed recent advances in novel brain targeting nddss for ad over the past years were summarised,True
12558063,10845649,A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.,12558063_0,alzheimer s disease ad a progressive degenerative disorder of the brain is believed to be the most common cause of dementia amongst the elderly ad is characterized by the presence of amyloid deposits and neurofibrillary tangles in the brain of afflicted individuals ad is associated with a loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning ad appears to have a heterogeneous etiology with a large percentage termed sporadic ad arising from unknown causes and a smaller fraction of early onset familial ad fad caused by mutations in one of several genes such as the beta amyloid precursor protein app and presenilins ps ps these proteins along with tau secretases such as beta amyloid cleaving enzyme bace and apolipoprotein e play important roles in the pathology of ad on therapeutic fronts there is significant research underway in the development of new inhibitors for bace ps and gamma secretase as targets for treatment of ad there is also a remarkable advancement in understanding the function of cholinesterase che in the brain and the use of che inhibitors in ad a new generation of acetyl and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for ad the development of vaccination strategies anti inflammatory agents cholesterol lowering agents anti oxidants and hormone therapy are examples of new approaches for treating or slowing the progression of ad in addition nutritional genetic and environmental factors highlight more effective preventive strategies for ad developments of early diagnostic tools and of quantitative markers are critical to better follow the course of the disease and to evaluate different therapeutic strategies in this review we attempt to critically examine recent trends in ad research from molecular genetic to clinical areas we discuss various neurobiological mechanisms that provide the basis of new targets for ad drug development all these current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the ad brain in order to effectively diagnose and prevent their occurrence,True
27796744,12511221,Molecular and Therapeutic Targets of Genistein in Alzheimer's Disease.,27796744_0,alzheimer s disease ad is a devastating brain disorder characterized by an increased level of amyloid beta a peptide deposition and neuronal cell death leading to an impairment of learning and thinking skills the a deposition is a key factor in senile plaques of the ad brain which cause the elevation of intracellular calcium ions and the production of formidable free radicals both of which greatly contribute to the ad associated cascade leading to unstoppable neuronal loss in the hippocampal region of the brain natural products are currently considered as an alternative strategy for the discovery of novel multipotent drugs against ad they include the naturally occurring dietary soy isoflavone genistein which has been recognized to possess several health promoting effects genistein has been mainly focused because of its potential on amelioration of a induced impairment and its antioxidant capacity to scavenge the free radicals produced in ad it can also directly interact with the targeted signaling proteins and stabilize their activity to prevent ad an improved understanding of the direct interactions between genistein and target proteins would contribute to the further development of ad treatment this review mainly focuses on molecular targets and the therapeutic effects regulated by genistein which has the ability to directly target the a peptide and to control its activity involved in intracellular signaling pathways which otherwise would lead to neuronal death in the hippocampal region of the ad brain,True
34813026,8608577,Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease.,34813026_0,alzheimer s disease ad is a major contributor of dementia leading to the degeneration of neurons in the brain with major symptoms like loss of memory and learning many evidences suggest the involvement of neuroinflammation in the pathology of ad cytokines including tnf and il are also found increasing the bace activity and expression of nf b resulting in generation of a in ad brain following the interaction of a with microglia and astrocytes other inflammatory molecules also get translocated to the site of inflammation by chemotaxis and exaggerate neuroinflammation various pathways like nf b p mapk akt mtor caspase nitric oxide and cox trigger microglia to release inflammatory cytokines ppar agonists like pioglitazone increases the phagocytosis of a and reduces inflammatory cytokine il celecoxib and roficoxib like selective cox inhibitors also ameliorate neuroinflammation non selective cox inhibitor indomethacin is also potent inhibitor of inflammatory mediators released from microglia mitophagy process is considered quite helpful in reducing inflammation due to microglia as it promotes the phagocytosis of over activated microglial cells and other inflammatory cells mitophagy induction is also beneficial in the removal of damaged mitochondria and reduction of infiltration of inflammatory molecules at the site of accumulation of the damaged mitochondria targeting these pathways and eventually ameliorating the activation of microglia can mitigate neuroinflammation and come out as a better therapeutic option for the treatment of alzheimer s disease,True
33371834,10454825,Potential Epigenetic Targets for Combating Alzheimer's Disease.,33371834_0,memory remains an obligatory regime of the human brain and impaired memory causes serious obstacles in our everyday life alzheimer s disease ad is one such neurodegenerative disease which mostly affects the elderly population above the age of marked by cognitive impairment of memory besides the known targets of ad against the several etiologies known to date the zone of epigenetics has recently evolved as an ingenious field in ad epigenetic modifications do not affect dna sequence but only long term gene expression considering the complex multifactorial nature of ad we herein discuss the various epigenetic targets which might give rise to potential therapeutic approaches we reviewed the possible epigenetic targets for ad like hdac sirtuins glial cells mirna and epigenetic modifications like dna methylation a deeper insight into these target areas can surely evolve ad diagnosis and therapeutics,True
21550318,12828788,Biomarkers in Alzheimer's disease drug development.,21550318_0,developing new therapies for alzheimer s disease ad is critically important to avoid the impending public health disaster imposed by this common disorder means must be found to prevent delay the onset or slow the progression of ad these goals will be achieved by identifying disease modifying therapies and testing them in clinical trials biomarkers play an increasingly important role in ad drug development in preclinical testing they assist in decisions to develop an agent biomarkers in phase i provide insights into toxic responses and drug metabolism and in phase ii proof of concept trials they facilitate go no go decisions and dose finding biomarkers can play a role in identifying presymptomatic patients or specific patient subgroups they can provide evidence of target engagement before clinical changes can be expected brain imaging can serve as a primary outcome in phase ii trials and as a key secondary outcome in phase iii trials magnetic resonance imaging is currently best positioned for use in large multicenter clinical trials cerebrospinal fluid csf measures of amyloid beta protein a tau protein and hyperphosphorylated tau p tau protein are sensitive and specific to the diagnosis of ad and may serve as inclusion criteria and possibly as outcomes in clinical trials targeting relevant pathways plasma measures of a are of limited diagnostic value but may provide important information as a measure of treatment response a wide variety of measures of detectable products of cellular processes are being developed as possible biomarkers accessible in the cerebrospinal fluid and plasma or serum surrogate markers that can function as outcomes in pivotal trials and reliably predict clinical outcomes are needed to facilitate primary prevention trials of asymptomatic persons where clinical measures may be of limited value fit for purpose biomarkers are increasingly available to guide ad drug development decisions,True
29484980,11354546,Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.,29484980_0,the discovery of cannabinoid receptors at the beginning of the s cb cloned in and cb cloned in and the availability of selective and potent cannabimimetics could only be justified by the existence of endogenous ligands that are capable of binding to them thus the characterisation and cloning of the first cannabinoid receptor cb led to the isolation and characterisation of the first endocannabinoid arachidonoylethanolamide aea two years later and the subsequent identification of a family of lipid transmitters known as the fatty acid ester arachidonoylglycerol ag the endogenous cannabinoid system is a complex signalling system that comprises transmembrane endocannabinoid receptors their endogenous ligands the endocannabinoids the specific uptake mechanisms and the enzymatic systems related to their biosynthesis and degradation the endocannabinoid system has been implicated in a wide diversity of biological processes in both the central and peripheral nervous systems including memory learning neuronal development stress and emotions food intake energy regulation peripheral metabolism and the regulation of hormonal balance through the endocrine system in this context this article will review the current knowledge of the therapeutic potential of cannabinoid receptor as a target in alzheimer s disease and other less well known diseases that include among others multiple sclerosis bone metabolism and fragile x syndrome the therapeutic applications will be addressed through the study of cannabinoid agonists acting as single drugs and multi target drugs highlighting the cb receptor agonist,True
21199770,12163420,Therapeutic targets in Alzheimer's disease and related tauopathies.,21199770_0,alzheimer s disease is a progressive neurodegenerative disease that is characterized histopathologically by the presence of plaques mainly composed of abeta amyloid and the tangles mainly composed of hyperphosphorylated tau to date there is no treatment that can reverse the disease and all the current therapeutics is directed to cope with the symptoms of the disease here we describe the efforts dedicated to attack the plaques and in more detail the process of neurofibrillary degeneration linked to the presence of the hyperphosphorylated microtubule associated protein tau we have identified the different putative targets for therapeutics and the current knowledge on them,True
23542729,12608195,Liver X receptors: emerging therapeutic targets for Alzheimer's disease.,23542729_0,alzheimer s disease ad is a complex neurodegenerative disorder typified by the pathological accumulation of amyloid peptides a and neurofibrillary tangles within the brain culminating to cognitive impairment epidemiological and biochemical data have suggested a link between cholesterol content app amyloid precursor protein processing a inflammation and ad the intricacy of the disease presents considerable challenges for the development of newer therapeutic agents liver x receptors lxra and lxr are oxysterol activated nuclear receptors that play essential role in lipid and glucose homeostasis steroidogenesis and inflammatory responses lxr signalling impacts the development of ad pathology through multiple pathways reports indicate that genetic loss of either lxra or lxr in app ps transgenic mice results in increased amyloid plaque load studies also suggest that ligand activation of lxrs in tg mice enhanced the expression of genes linked with cholesterol efflux e g apoe abca down regulated app processing and a production with significant improvement in memory functions lxr agonists have also depicted to inhibit neuroinflammation through modulation of microglial phagocytosis and by repressing the expression of cox mcp and inos in glial cells this review summarizes in brief the biology of lxrs with an emphasis on their probable pathophysiological mechanisms that may elicit the defending role of these receptors in brains of ad patients,True
34181171,8236749,Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.,34181171_0,alzheimer s disease ad is a neurodegenerative old age disease that is complex multifactorial unalterable and progressive in nature the currently approved therapy includes cholinesterase inhibitors nmda receptor antagonists and their combination therapy provides only temporary symptomatic relief sincere efforts have been made by the researchers globally to identify new targets discover and develop novel therapeutic agents for the treatment of ad this brief review article is intended to cover the recent advances in drug development and emerging therapeutic agents for ad acting at different targets the article is compiled using various scientific online databases and by referring to clinicaltrials gov and alzforum alzforum org websites the upcoming therapies act on one or more targets including amyloids secretases a sub sub production amyloid deposition and immunotherapy tau proteins tau phosphorylation aggregation and immunotherapy and neuroinflammation in addition to other miscellaneous targets despite the tremendous improvement in our understanding of the underlying pathophysiology of ad only aducanumab was approved by fda for the treatment of ad in years i e since hence it is concluded that novel therapeutic strategies are required to discover and develop therapeutic agents to fight against the century old ad,True
29246246,,Rho GTPases as therapeutic targets in Alzheimer's disease.,29246246_0,the progress we have made in understanding alzheimer s disease ad pathogenesis has led to the identification of several novel pathways and potential therapeutic targets rho gtpases have been implicated as critical components in ad pathogenesis but their various functions and interactions make understanding their complex signaling challenging to study recent advancements in both the field of ad and rho gtpase drug development provide novel tools for the elucidation of rho gtpases as a viable target for ad herein we summarize the fluctuating activity of rho gtpases in various stages of ad pathogenesis and in several in vitro and in vivo ad models we also review the current pharmacological tools such as nsaids rhoa rock rac and cdc inhibitors used to target rho gtpases and their use in ad related studies finally we summarize the behavioral modifications following rho gtpase modulation in several ad mouse models as key regulators of several ad related signals rho gtpases have been studied as targets in ad however a consensus has yet to be reached regarding the stage at which targeting rho gtpases would be the most beneficial the studies discussed herein emphasize the critical role of rho gtpases and the benefits of their modulation in ad,False
40064874,11893799,Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics.,40064874_0,lipid nanoparticles have shown success in targeting major organs such as the liver spleen and lungs but crossing the blood brain barrier bbb remains a major challenge effective brain targeted delivery systems are essential for advancing gene therapy for neurological diseases but remain limited by low transport efficiency and poor nucleic acid stability here we report a library of ionizable lipids based on the tetrahydroisoquinoline structure of protoberberine alkaloids designed to improve bbb penetration via dopamine d receptor mediated endocytosis these nanoparticles offer three key advantages enhanced brain uptake improved nucleic acid stability through poly a self assembly and minimal immunogenicity with inherent neuroprotective properties in murine models they demonstrate therapeutic potential in alzheimer s disease glioma and cryptococcal meningitis this berberine inspired delivery system integrates precise receptor targeting with nucleic acid stabilization offering a promising platform for brain targeted therapeutics,True
35807370,,Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules.,35807370_0,alzheimer s disease ad is a common progressive and devastating neurodegenerative disorder that mainly affects the elderly microglial dysregulation amyloid beta a plaques and intracellular neurofibrillary tangles play crucial roles in the pathogenesis of ad in the brain microglia play roles as immune cells to provide protection against virus injuries and diseases they have significant contributions in the development of the brain cognition homeostasis of the brain and plasticity multiple studies have confirmed that uncontrolled microglial function can result in impaired microglial mitophagy induced a accumulation and tau pathology and a chronic neuroinflammatory environment in the brain most of the genes that are associated with ad risk are highly expressed by microglia although it was initially regarded that microglia reaction is incidental and induced by dystrophic neurites and a plaques nonetheless it has been reported by genome wide association studies that most of the risk loci for ad are located in genes that are occasionally uniquely and highly expressed in microglia this finding further suggests that microglia play significant roles in early ad stages and they be targeted for the development of novel therapeutics in this review we have summarized the molecular pathogenesis of ad microglial activities in the adult brain the role of microglia in the aging brain and the role of microglia in ad we have also particularly focused on the significance of targeting microglia for the treatment of ad,False
29332579,11865952,Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules.,29332579_0,alzheimer s disease ad is a fatal neurodegenerative disorder having a complex aetiology with numerous possible drug targets there are targets that have been known for years while more new targets and theories have also emerged beta amyloid and cholinesterases are the most significant biological targets for finding curative treatment of ad the major class of drugs used for ad till now has been the cholinesterase che inhibitors other prevailing models of molecular pathogenesis in ad include neurofibrillary tangles nfts and amyloid deposition tryptophan degradation pathway kinase and phosphatase activity imbalance and neuroinflammation the beta amyloid aggregation initiates flow of events resulting in neurotoxicity and finally clinical pathogenesis of ad furthermore apoe is another very significant entity involved in repairing and maintaining the neurons and has important role in neurodegeneration neuroinflammation being the primmest symptom for ad is essential to focus on multiple factors and complexity in interlinking disease progression pose huge challenge to find one complete curing drug with so many promising molecules having multiform pharmacological profile from all over the world however facing failures in clinical trials indicates the need to consider all aspects of the old as well as new therapeutic targets of ad until the disease mechanism is better understood it is likely that multiple targeting symptomatic and diseasemodifying is the way forward most recent approaches to find anti alzheimer s agents have focused on multi target directed agents that include targeting all glorious targets hypothesized against ad new identification of prototype candidates that could be starting point of a new way of thinking drug design has been done and many drug candidates are under preclinical evaluation the main focus of this review is to discuss the recent understanding of key targets and the development of potential therapeutic agents for the treatment of ad it also documents the current therapeutic agents in clinical trials and under development based on their main mode of action,False
38286338,12844234,"Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management.",38286338_0,alzheimer s disease ad is a neurodegenerative disorder that escalates with time exerting a significant impact on physical and mental health and leading to death the prevalence of ad is progressively rising along with its associated economic burden and necessitates effective therapeutic approaches in the near future this review paper aims to offer an insightful overview of disease pathogenesis current fda approved drugs and drugs in different clinical phases it also explores innovative formulations and drug delivery strategies focusing on nanocarriers and long acting medications lams to enhance treatment efficacy and patient adherence the review also emphasizes preclinical evidence related to nanocarriers and their potential to improve drug bioavailability pharmacokinetics and pharmacodynamics parameters while also highlighting their ability to minimize systemic side effects by providing a comprehensive analysis this review furnishes valuable insights into different pathophysiological mechanisms for future drug development it aims to inform the development of treatment strategies and innovative formulation approaches for delivering existing molecules in alzheimer s disease ultimately striving to improve patient compliance,True
38382942,12339169,Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets.,38382942_0,alzheimer s disease ad is one of the most common neurodegenerative diseases due to the complexity of the disorder and the presence of the blood brain barrier bbb its drug discovery and development are facing enormous challenges especially after several failures of monoclonal antibody mab trials nevertheless the food and drug administration s approval of the mab aducanumab has ushered in a new day as we better understand the disease s pathogenesis and identify novel intracerebral therapeutic targets antibody based therapies have advanced over the past few years the mab drugs targeting amyloid or hyperphosphorylated tau protein are the focus of the current research massive neuronal loss and glial cell mediated inflammation are also the vital pathological hallmarks of ad signaling a new direction for research on mab drugs we have elucidated the mechanisms by which ad specific mabs cross the bbb to bind to targets in order to investigate therapeutic approaches to treat ad this review focuses on the promising mabs targeting intracerebral dysfunction and related strategies to cross the bbb,True
38853102,,Multi-target drugs for Alzheimer's disease.,38853102_0,alzheimer s disease ad a leading cause of dementia increasingly challenges our healthcare systems and society traditional therapies aimed at single targets have fallen short owing to the complex multifactorial nature of ad that necessitates simultaneous targeting of various disease mechanisms for clinical success therefore targeting multiple pathologies at the same time could provide a synergistic therapeutic effect the identification of new disease targets beyond the classical hallmarks of ad offers a fertile ground for the design of new multi target drugs mtds and building on existing compounds have the potential to yield in successful disease modifying therapies this review discusses the evolving landscape of mtds focusing on their potential as ad therapeutics analysis of past and current trials of compounds with multi target activity underscores the capacity of mtds to offer synergistic therapeutic effects and the flourishing genetic understanding of ad will inform and inspire the development of mtd based ad therapies,False
25045220,4101776,Diverse molecular targets for therapeutic strategies in Alzheimer's disease.,25045220_0,alzheimer s disease ad is the most common form of dementia caused by neurodegenerative process and is tightly related to amyloid a and neurofibrillary tangles the lack of early diagnostic biomarker and therapeutic remedy hinders the prevention of increasing population of ad patients every year in spite of accumulated scientific information numerous clinical trials for candidate drug targets have failed to be preceded into therapeutic development therefore ad related sufferers including patients and caregivers are desperate to seek the solution also effective ad intervention is desperately needed to reduce ad related societal threats to public health in this review we summarize various drug targets and strategies in recent preclinical studies and clinical trials for ad therapy allopathic treatment immunotherapy a production aggregation modulator tau targeting therapy and metabolic targeting some has already failed in their clinical trials and the others are still in various stages of investigations both of which give us valuable information for future research in ad therapeutic development,False
35635955,12771443,Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.,35635955_0,alzheimer s disease is a chronic and progressive brain neurodegenerative disease affecting over million people globally currently no effective treatment is available due to multiple factors involved in the progression of ad given that the numerous ad related targets in the disease network the multi target directed ligands mtdls strategy are considered as the promising strategy to treat ad herein the multi target compounds with without ches are in clinical and in progress are reviewed to further characterize the drug likeness and adme properties are calculated using the qikprop this review will provide highlights for the treatment of ad,True
23217740,12799483,A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.,23217740_0,a immunotherapy is a promising therapeutic approach for alzheimer s disease preclinical studies demonstrate that plaque prevention is possible however the more relevant therapeutic removal of existing plaque has proven elusive monoclonal antibodies in development target both soluble and insoluble a peptide we hypothesized that antibody specificity for deposited plaque was critical for plaque removal since soluble a peptide would block recognition of deposited forms we developed a plaque specific antibody that targets a modified a peptide a p which showed robust clearance of pre existing plaque without causing microhemorrhage interestingly a comparator n terminal a antibody d which binds both soluble and insoluble a lacked efficacy for lowering existing plaque but manifested a significant microhemorrhage liability mechanistic studies suggested that the lack of efficacy for d was attributed to poor target engagement in plaques these studies have profound implications for the development of therapeutic a antibodies for alzheimer s disease,True
22015920,3206090,Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.,22015920_0,neurodegenerative diseases exemplified by alzheimer s disease and huntington s disease are characterized by progressive neuropsychiatric dysfunction and loss of specific neuronal subtypes although there are differences in the exact sites of pathology and the clinical profiles of these two conditions only partially overlap considerable similarities in disease mechanisms and pathogenic pathways can be observed these shared mechanisms raise the possibility of exploiting common therapeutic targets for drug development as huntington s disease has a monogenic cause it is possible to accurately identify individuals who carry the huntington s disease mutation but do not yet manifest symptoms these individuals could act as a model for alzheimer s disease to test therapeutic interventions that target shared pathogenic pathways,False
33638130,12839151,Intranasal drug delivery for treatment of Alzheimer's disease.,33638130_0,the alzheimer s disease is a neurodegenerative condition with severe consequences interfering with patient quality of life it is characterized as a progressive and irreversible brain disorder hampering memory and thinking affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation the conventional treatment occurs by the oral route but it presents relevant drawbacks such as low bioavailability fast metabolism limited brain exposure and undesirable side effects the intranasal route has been proposed as a promising alternative to deliver drugs and improve the alzheimer s disease treatment still there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety the aim of this review is to perform an overview on the strategies for drug intranasal delivery for alzheimer s disease treatment the advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed a special focus is given on the use of permeation enhancers the types of intranasal drug delivery devices as well as possible toxicity concerns,True
33652356,12858709,Alzheimer's disease and its treatment by different approaches: A review.,33652356_0,alzheimer s disease ad is a neurodegenerative disorder that impairs mental ability development and interrupts neurocognitive function this neuropathological condition is depicted by neurodegeneration neural loss and development of neurofibrillary tangles and a plaques there is also a greater risk of developing ad at a later age for people with cardiovascular diseases hypertension and diabetes in the biomedical sciences effective treatment for alzheimer s disease is a severe obstacle there is no such treatment to cure alzheimer s disease the drug present in the market show only symptomatic relief the cause of alzheimer s disease is not fully understood and the blood brain barrier restricts drug efficacy are two main factors that hamper research stem cell based therapy has been seen as an effective secure and creative therapeutic solution to overcoming ad because of ad s multifactorial nature and inadequate care current developments in nanotechnology often offer possibilities for the delivery of active drug candidates to address certain limitations the key nanoformulations being tested against ad include polymeric nanoparticles np inorganic nps and lipid based nps nano drug delivery systems are promising vehicles for targeting several therapeutic moieties by easing drug molecules penetration across the cns and improving their bioavailability in this review we focus on the causes of the ad and their treatment by different approaches,True
38095822,12627486,Lecanemab: More Questions Than Answers!,38095822_0,the approval of lecanemab by the us food and drug administration has been touted as a defining moment in the treatment of alzheimer s disease lecanemab an anti amyloid beta monoclonal antibody is the first alzheimer s disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase iii trials however there have been many questions raised over the clinical relevance of the otherwise minimal cognitive improvements furthermore its rapid approval has been mired in controversy in addition to the reports of adverse events such as amyloid related imaging abnormalities and several deaths of participants in the lecanemab trials here we analyze the evidence supporting lecanemab as an amyloid beta therapy and also discuss the concerns raised about its efficacy and safety,True
32284421,7196825,Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.,32284421_0,the blood brain barrier bbb presents a significant challenge for treating brain disorders the hippocampus is a key target for novel therapeutics playing an important role in alzheimer s disease ad epilepsy and depression preclinical studies have shown that magnetic resonance mr guided low intensity focused ultrasound fus can reversibly open the bbb and facilitate delivery of targeted brain therapeutics we report initial clinical trial results evaluating the safety feasibility and reversibility of bbb opening with fus treatment of the hippocampus and entorhinal cortex ec in patients with early ad six subjects tolerated a total of fus treatments with no adverse events and neither cognitive nor neurological worsening post fus contrast mri revealed immediate and sizable hippocampal parenchymal enhancement indicating bbb opening followed by bbb closure within h the average opening was of the targeted fus volume which corresponds to of the overall hippocampus volume we demonstrate that fus can safely noninvasively transiently reproducibly and focally mediate bbb opening in the hippocampus ec in humans this provides a unique translational opportunity to investigate therapeutic delivery in ad and other conditions,False
33444675,,Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease.,33444675_0,alzheimer s disease ad is the most common neurodegenerative disease and its incidence is increasing worldwide with increased lifespan currently there is no effective treatment to cure or prevent the progression of ad which indicates the need to develop novel therapeutic targets and agents sirtuins especially sirt a mitochondrial deacetylase are nad dependent histone deacetylases involved in aging and longevity accumulating evidence indicates that sirt dysfunction is strongly associated with pathologies of ad hence therapeutic modulation of sirt activity may be a novel application to ameliorate the pathologies of ad natural products commonly used in traditional medicine have wide utility and appear to have therapeutic benefits for the treatment of neurodegenerative diseases such as ad the present review summarizes the currently available natural sirt activators and their potentially neuroprotective molecular mechanisms of action that make them a promising agent in the treatment and management of neurodegenerative diseases such as ad,False
15723159,11206728,"Alzheimer's associated inflammation, potential drug targets and future therapies.",15723159_0,alzheimer s disease is the most common cause of dementia in the elderly population the most widely used treatment for alzheimer s disease at present is acetylcholinesterase inhibitors which aim to prolong cognitive function through increased synaptic activity without providing neuroprotection this treatment is only symptomatic and provides modest outcomes for patients the recent elucidation of the inflammatory pathways involved in alzheimer s disease however has opened doors for better treatment and prevention by identification of areas of therapeutic intervention that target the cause of the disease rather than the symptoms this review describes the inflammatory pathways that are thought to be present in alzheimer s disease and some of the new therapies that have shown promise via alteration or inhibition of these pathways some of the therapies included in this review which have already demonstrated beneficial effects in the treatment of alzheimer s disease or have the potential to do so are nonsteroidal anti inflammatory drugs statins rage antagonists and antioxidants,True
29298417,,Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.,29298417_0,receptors show promise for the transport of monoclonal antibodies mabs across the blood brain barrier however safety liabilities associated with peripheral receptor binding and fc effector function have been reported we present the brain shuttle mab bs mab technology and we investigate the role of fc effector function in vitro and in an fc receptor fc r humanized mouse model strong first infusion reactions firs were observed for a conventional mab against transferrin receptor tfr with a wild type immunoglobulin g igg fc fc effector dead constructs completely eliminated all firs remarkably no fir was observed for the bs mab construct with a native igg fc function using various bs mab constructs we show that tfr binding through the c terminal bs module attenuates fc fc r interactions primarily because of steric hindrance nevertheless bs mabs maintain effector function activity when binding their brain target thus mabs with full effector function can be transported in a stealth mode in the periphery while fully active when engaged with their brain target,False
37386015,10310781,"Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.",37386015_0,amyloid protein a is the main component of neuritic plaques in alzheimer s disease ad and its accumulation has been considered as the molecular driver of alzheimer s pathogenesis and progression a has been the prime target for the development of ad therapy however the repeated failures of a targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of alzheimer s drug has followed the correct course however the recent successes of a targeted trials have assuaged those doubts in this review we discussed the evolution of the amyloid cascade hypothesis over the last years and summarized its application in alzheimer s diagnosis and modification in particular we extensively discussed the pitfalls promises and important unanswered questions regarding the current anti a therapy as well as strategies for further study and development of more feasible a targeted approaches in the optimization of ad prevention and treatment,True
39000217,,Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.,39000217_0,peroxisome proliferator activated receptors ppars may play an important role in the pathomechanism pathogenesis of alzheimer s disease ad and several other neurological neuropsychiatric disorders ad leads to progressive alterations in the redox state ion homeostasis lipids and protein metabolism significant alterations in molecular processes and the functioning of several signaling pathways result in the degeneration and death of synapses and neuronal cells leading to the most severe dementia peroxisome proliferator activated receptor alpha ppar is among the processes affected by ad it regulates the transcription of genes related to the metabolism of cholesterol fatty acids other lipids and neurotransmission mitochondria biogenesis and function ppar is involved in the cholesterol transport to mitochondria the substrate for neurosteroid biosynthesis ppar coding enzymes such as sulfotransferases which are responsible for neurosteroid sulfation the relation between ppar and cholesterol neurosteroids may have a significant impact on the course and progression of neurodegeneration neuroprotection processes unfortunately despite many years of intensive studies the pathogenesis of ad is unknown and therapy for ad and other neurodegenerative diseases is symptomatic presenting a significant goal and challenge today this review presents recent achievements in therapeutic approaches for ad which are targeting ppar and its relation to cholesterol and neurosteroids in ad and neuropsychiatric disorders,False
23677646,12752569,β-Arrestins as potential therapeutic targets for Alzheimer's disease.,23677646_0,arrestins represent a small family of g protein coupled receptors gpcrs regulators which provide modulating effects by facilitating desensitization and internalization of gpcrs as well as initiating their own signalings recent reports have demonstrated that arrestins levels were correlated with amyloid peptide a pathology in brains of alzheimer s disease ad patients and animal models arrestins could enhance the activity of secretase via interacting with anterior pharynx defective subunit which increased a production and contributed to the pathogenesis of ad in addition a induced internalization of adrenergic receptor internalization and loss of dendritic spine in neurons were proven to be mediated by arrestins further establishing their pathogenic role in ad more importantly deletion of arrestins markedly attenuated ad pathology without causing any gross abnormality here we review the evidence about the roles of arrestins in the progression of ad in addition the established and postulated mechanisms by which arrestins mediated in ad pathogenesis are also discussed based on the role of arrestins in ad pathogenesis genetically or pharmacologically targeting arrestins might provide new opportunities for ad treatment,True
34544351,12423730,"Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development.",34544351_0,alzheimer s disease is inflating worldwide and is combatted by only a few approved drugs at best these drugs treat symptomatic conditions by targeting cholinesterase and n methyl d aspartate receptors most of the clinical trials in progress are focused on developing disease modifying agents that aim at single targets the one drug one target approach is failing in the case of alzheimer s disease due to its labyrinth etiopathogenesis traditional medicinal systems like ayurveda use a holistic approach encompassing the legion of medicinal plants exhibiting multimodal activity recent advances in high throughput technologies have catapulted the research in the arena of ayurveda specifically in identifying plants with potent anti alzheimer s disease properties and their phytochemical characterization nonetheless clinical trials of very few herbal medicines are in progress this review is a compendium of indian plants and ayurvedic medicines against alzheimer s disease and their paraphernalia a record of plants that are found in india with anti alzheimer s disease potential and about phytochemicals from medicinal plants have been solicited with the hope of exploring the unexplored further the molecular targets of phytochemicals isolated from commonly used medicinal plants such as acorus calamus bacopa monnieri convolvulus pluricaulis tinospora cordifolia and withania somnifera have been reviewed with respect to their multidimensional property such as antioxidant anti inflammation anti aggregation synaptic plasticity modulation cognition and memory enhancing activity in addition the strengths and challenges in ayurvedic medicine that limit its use as mainstream therapy are discussed and a framework for the development of herbal medicine has been proposed,True
32804096,7579750,Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease.,32804096_0,numerous experimental and postmortem studies have increasingly reported dystrophic axons and dendrites and alterations of dendritic spine morphology and density in the hippocampus as prominent changes in the early stages of alzheimer s disease ad furthermore these alterations tend to correlate well with the progressive cognitive decline observed in ad for these reasons and because these neurite structures have a capacity to re grow re establish lost connections and are critical for learning and memory there is compelling evidence to suggest that therapeutic interventions aimed at preventing their degradation or promoting their regrowth may hold tremendous promise in preventing the progression of ad in this regard collapsin response mediator proteins crmps a family of phosphoproteins playing a major role in axon guidance and dendritic growth are especially interesting the roles these proteins play in neurons and immune cells are reviewed here,False
21718217,3156324,Nuclear receptors as therapeutic targets for Alzheimer's disease.,21718217_0,alzheimer s disease ad is characterized by the accumulation and extensive deposition of amyloid a in the parenchyma of the brain this accumulation of amyloid is associated with perturbations in synaptic function impairments in energy metabolism and induction of a chronic inflammatory response which acts to promote neuronal loss and cognitive impairment currently there are no drugs that target the underlying mechanisms of ad here we propose a class of nuclear receptors as novel and promising new therapeutic targets for ad this review summarizes the literature on nuclear receptors and their effects on ad related pathophysiology nuclear receptors are attractive targets for the treatment of ad due to their ability to facilitate degradation of a affect microglial activation and suppress the inflammatory milieu of the brain liver x receptor agonists have proven difficult to move into clinical trials as long term treatment results in hepatic steatosis it is our view that ppar activation remains a promising avenue for the treatment for ad however the poor bbb permeability of the currently available agonists and the negative outcome of the phase iii clinical trials are likely to diminish interest in pursuing this target,False
35300725,8932191,Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.,35300725_0,alzheimer s disease ad is the most common neurodegenerative disease in the elderly worldwide however the complexity of ad pathogenesis leads to discrepancies in the understanding of this disease and may be the main reason for the failure of ad drug development fortunately many ongoing preclinical and clinical studies will continually open up avenues to unravel disease mechanisms and guide strategies for ad diagnosis and drug development for example immunotherapeutic strategies targeting amyloid a and tau proteins were once deemed almost certainly effective in clinical treatment due to the excellent preclinical results however the repeated failures of clinical trials on vaccines and humanized anti a and anti tau monoclonal antibodies have resulted in doubts on this strategy recently a new anti a monoclonal antibody aducanumab has been approved by the us food and drug administration which brings us back to the realization that immunotherapy strategies targeting a may be still promising meanwhile immunotherapies based on other targets such as tau microglia and gut brain axis are also under development further research is still needed to clarify the forms and epitopes of targeted proteins to improve the accuracy and effectiveness of immunotherapeutic drugs in this review we focus on the immunotherapies based on a tau and microglia and their mechanisms of action in ad in addition we present up to date advances and future perspectives on immunotherapeutic strategies for ad,True
31797761,12277872,Progress in Target Drug Molecules for Alzheimer's Disease.,31797761_0,alzheimer s disease ad is a chronic neurodegenerative disease that widespread in the elderly the etiology of ad is complicated and its pathogenesis is still unclear although there are many researches on anti ad drugs they are limited to reverse relief symptoms and cannot treat diseases therefore the development of high efficiency anti ad drugs with no side effects has become an urgent need based on the published literature this paper summarizes the main targets of ad and their drugs and focuses on the research and development progress of these drugs in recent years,True
38590098,12461629,Potential Alzheimer's disease drug targets identified through microglial biology research.,38590098_0,microglia the primary immune cells in the brain play multifaceted roles in alzheimer s disease ad microglia can potentially mitigate the pathological progression of ad by clearing amyloid beta a deposits in the brain and through neurotrophic support in contrast disproportionate activation of microglial pro inflammatory pathways as well as excessive elimination of healthy synapses can exacerbate neurodegeneration in ad the challenge therefore lies in discerning the precise regulation of the contrasting microglial properties to harness their therapeutic potential in ad this review examines the evidence relevant to the disease modifying effects of microglial manipulators in ad preclinical models the deleterious pro inflammatory effects of microglia in ad can be ameliorated via direct suppression or indirectly through metabolic manipulation epigenetic targeting and modulation of the gut brain axis furthermore microglial clearance of a deposits in ad can be enhanced via strategically targeting microglial membrane receptors lysosomal functions and metabolism given the intricate and diverse nature of microglial responses throughout the course of ad therapeutic interventions directed at microglia warrant a tactical approach this could entail employing therapeutic regimens which concomitantly suppress pro inflammatory microglial responses while selectively enhancing a phagocytosis,True
32006534,7047718,Glycogen synthase kinase-3 signaling in Alzheimer's disease.,32006534_0,alzheimer s disease ad is the most common form of neurodegenerative disorder with dementia accounting for approximately of the all cases currently million people in the u s are living with ad and by this number is expected to double resulting in a significant socio economic burden despite intensive research the exact mechanisms that trigger ad are still not known and at the present there is no cure for it in recent years many signaling pathways associated with ad neuropathology have been explored as possible candidate targets for the treatment of this condition including glycogen synthase kinase gsk gsk is considered a key player in ad pathophysiology since dysregulation of this kinase influences all the major hallmarks of the disease including tau phosphorylation amyloid production memory neurogenesis and synaptic function the present review summarizes the current understanding of the gsk neurobiology with particular emphasis on its effects on specific signaling pathways associated with ad pathophysiology moreover it discusses the feasibility of targeting gsk for ad treatment and provides a summary of the current research effort to develop gsk inhibitors in preclinical and clinical studies,False
36043720,12704319,Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets.,36043720_0,circular rnas circrnas as covalently closed single stranded noncoding rna molecules have been recently identified to involve in several biological processes principally through targeting micrornas among various neurodegenerative diseases nds accumulating evidence has proposed key roles for circrnas in the pathogenesis of alzheimer s disease ad although the exact relationship between these rna molecules and ad progression is not clear they have been believed to mostly act as mirna sponges or gene transcription modulators through the correlating with multiple proteins involved in the accumulation of amyloid a peptides as well as tau protein as ad s pathological hallmark more interestingly circrnas have also been reported to play diagnostic and therapeutic roles during the ad progression the literature review indicated that circrnas could essentially contribute to the onset and development of ad thus in the current review the circrnas biogenesis and functions are addressed at first and then the interplay between particular circrnas and ad is comprehensively discussed eventually the diagnostic and therapeutic significance of these noncoding rnas is briefly highlighted a large number of circrnas are expressed in the brain thereby these rna molecules are noticed as potential regulators of neural functions in healthy circumstances as well as in neurological disorders moreover circrnas have also been reported to have potential diagnostic and therapeutic capacities in relation to ad the most prevalent nd circrnas have been shown to act as sponges for mirnas thereby regulating the function of related mirnas including oxidative stress reduction of neuroinflammation and the formation and metabolism of a all of which developed in ad circrnas have also been proposed as biomarkers that have potential diagnostic capacities in ad despite these characteristics the use of circrnas as therapeutic targets and promising diagnostic biomarkers will require further investigation and characterization of the function of these rna molecules in ad,True
16491164,,Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease.,16491164_0,one characteristic of alzheimer s disease is a deficit in new memory formation numerous studies and reviews have investigated targeting the creb pathway for enhancing memory in diseases such as alzheimer s in addition the possibility of targeting the nuclear factor kappab nf kappab pathway for inflammatory conditions which also play a role in alzheimer s disease has been investigated interestingly recent data concerning nf kappab functioning indicates that the development of drugs targeting nf kappab regulation may prove beneficial for memory disorders however given the complexity of nf kappab functioning the most important challenge remaining is whether to enhance or inhibit the activation nf kappab future studies undoubtedly will focus on selected targets and optimal activation levels during critical stages of specific disease pathologies this short review summarizes past studies with creb describes nf kappab functioning and highlights new data on the potential role of nf kappab in new memory formation and alzheimer s disease,False
39218078,12190531,Emerging microglial biology highlights potential therapeutic targets for Alzheimer's disease.,39218078_0,alzheimer s disease is a chronic degenerative disease of the central nervous system which primarily affects elderly people and accounts for of dementia cases the current prevailing amyloid cascade hypothesis suggests that alzheimer s disease begins with the deposition of amyloid a in the brain major therapeutic strategies target a production aggregation and clearance although many clinical trials have shown that these therapeutic strategies are not sufficient to completely improve cognitive deficits in ad patients recent genome wide association studies have identified that multiple important regulators are the most significant genetic risk factors for alzheimer s disease especially in the innate immune pathways these genetic risk factors suggest a critical role for microglia highlighting their therapeutic potential in treating neurodegenerative diseases in this review we discuss how these recently documented ad risk genes affect microglial function and ad pathology and how they can be further targeted to regulate microglial states and slow ad progression especially the highly anticipated apoe and trem targets we focused on recent findings that modulation of innate and adaptive neuroimmune microenvironment crosstalk reverses cognitive deficits in ad patients we also considered novel strategies for microglia in ad patients,True
34072862,8199025,"When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.",34072862_0,alzheimer s disease ad is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas huntington s disease hd is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum although there have been numerous clinical trials for these diseases they have been unsuccessful research conducted over the past three decades by a large number of laboratories has demonstrated that abnormal actions of common kinases play a key role in the pathogenesis of both ad and hd as well as several other neurodegenerative diseases prominent among these kinases are glycogen synthase kinase gsk p mitogen activated protein kinase mapk and some of the cyclin dependent kinases cdks after a brief summary of the molecular and cell biology of ad and hd this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders the potential of targeting gsk p mapk and cdks as effective therapeutics is also discussed as is a brief discussion on the utilization of recently developed drugs that simultaneously target two or all three of these groups of kinases multi kinase inhibitors either by themselves or in combination with strategies currently being used such as immunotherapy or secretase inhibitors for ad and knockdown for hd could represent a more effective therapeutic approach for these fatal neurodegenerative diseases,False
37353152,10528676,siRNA drug delivery across the blood-brain barrier in Alzheimer's disease.,37353152_0,alzheimer s disease ad is a progressive neurodegenerative disease with a few fda approved drugs that provide modest symptomatic benefits and only two fda approved disease modifying treatments for ad the advancements in understanding the causative genes and non coding sequences at the molecular level of the pathophysiology of ad have resulted in several exciting research papers that employed small interfering rna sirna based therapy although sirna is being sought by academia and biopharma industries several challenges still need to be addressed we comprehensively report the latest advances in ad pathophysiology druggable targets ongoing clinical trials and the sirna based approaches across the blood brain barrier for addressing ad this review describes the latest delivery systems employed to address this barrier critical insights and future perspectives on sirna therapy for ad are also provided,False
36430432,9697769,Alzheimer's Disease: Treatment Strategies and Their Limitations.,36430432_0,alzheimer s disease ad is the most frequent case of neurodegenerative disease and is becoming a major public health problem all over the world many therapeutic strategies have been explored for several decades however there is still no curative treatment and the priority remains prevention in this review we present an update on the clinical and physiological phase of the ad spectrum modifiable and non modifiable risk factors for ad treatment with a focus on prevention strategies then research models used in ad followed by a discussion of treatment limitations the prevention methods can significantly slow ad evolution and are currently the best strategy possible before the advanced stages of the disease indeed current drug treatments have only symptomatic effects and disease modifying treatments are not yet available drug delivery to the central nervous system remains a complex process and represents a challenge for developing therapeutic and preventive strategies studies are underway to test new techniques to facilitate the bioavailability of molecules to the brain after a deep study of the literature we find the use of soft nanoparticles in particular nanoliposomes and exosomes as an innovative approach for preventive and therapeutic strategies in reducing the risk of ad and solving problems of brain bioavailability studies show the promising role of nanoliposomes and exosomes as smart drug delivery systems able to penetrate the blood brain barrier and target brain tissues finally the different drug administration techniques for neurological disorders are discussed one of the promising therapeutic methods is the intranasal administration strategy which should be used for preclinical and clinical studies of neurodegenerative diseases,True
38614367,12858709,Treating Alzheimer's disease using nanoparticle-mediated drug delivery strategies/systems.,38614367_0,the administration of promising medications for the treatment of neurodegenerative disorders ndds such as alzheimer s disease ad parkinson s disease pd huntington s disease hd and amyotrophic lateral sclerosis als is significantly hampered by the blood brain barrier bbb nanotechnology has recently come to light as a viable strategy for overcoming this obstacle and improving drug delivery to the brain with a focus on current developments and prospects this review article examines the use of nanoparticles to overcome the bbb constraints to improve drug therapy for ad the potential for several nanoparticle based approaches such as those utilizing lipid based polymeric and inorganic nanoparticles to enhance drug transport across the bbb are highlighted to shed insight on their involvement in aiding effective drug transport to the brain methods of nanoparticle mediated drug delivery such as surface modifications functionalization and particular targeting ligands are also investigated the article also discusses the most recent findings on innovative medication formulations encapsulated within nanoparticles and the therapeutic effects they have shown in both preclinical and clinical testing this sector has difficulties and restrictions such as the need for increased safety scalability and translation to clinical applications however the major emphasis of this review aims to provide insight and contribute to the knowledge of how nanotechnology can potentially revolutionize the worldwide treatment of ndds particularly ad to enhance clinical outcomes,True
32784025,12698819,Role of tau protein in Alzheimer's disease: The prime pathological player.,32784025_0,alzheimer s disease ad is a prevalently found tauopathy characterized by memory loss and cognitive insufficiency ad is an age related neurodegenerative disease with two major hallmarks which includes extracellular amyloid plaques made of amyloid a and intracellular neurofibrillary tangles of hyperphosphorylated tau with population aging worldwide there is an indispensable need for treatment strategies that can potentially manage this developing dementia despite broad researches on targeting a in the past two decades research findings on a targeted therapeutics failed to prove efficacy in the treatment of ad tau protein with its extensive pathological role in several neurodegenerative diseases can be considered as a promising target candidate for developing therapeutic interventions the abnormal hyperphosphorylation of tau plays detrimental pathological functions which ultimately lead to neurodegeneration this review will divulge the importance of tau in ad pathogenesis the interplay of a and tau the pathological functions of tau and potential therapeutic strategies for an effective management of neuronal disorders,True
39930497,11809104,Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.,39930497_0,alzheimer s disease ad is a distinctive form of dementia characterized by age related cognitive decline and memory impairment a key hallmark of ad is the irreversible overaccumulation of beta amyloid a in the brain associated with neuroinflammation and neuronal death although a clearance and immunoregulation have been the major therapeutic strategies for ad highly selective transport across the blood brain barrier bbb negatively affects the delivery efficacy of the drugs without the ability to cross the bbb in this review we discuss the potential of lipid based nanoparticles lbns as promising vehicles for drug delivery in ad treatment lbns composed of phospholipid mono or bilayer have attracted attention due to their exceptional cellular penetration capabilities and drug loading capabilities which also facilitate cargo transcytosis across the bbb recent advances in the development and engineering of lbns overcome the existing limitations of the current clinical approaches for ad treatment by addressing off target effects and low therapeutic efficacy here we review the transport pathways across the bbb as well as various types of lbns for ad therapy including exosomes liposomes solid lipid nanoparticles slns and nanostructured lipid carriers nlcs to elucidate their distinctive properties preparation methodologies and therapeutic efficacy thereby offering innovative avenues for novel drug development for clinical translation in ad therapy,True
38513667,,"P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.",38513667_0,neuronal loss is the central issue in alzheimer s disease ad yet no treatment developed so far can halt ad associated neurodegeneration here we developed a monoclonal antibody mab a against site phosphorylated human tau p tau and observed that p tau levels positively correlated with brain atrophy and cognitive impairment in ad patients intranasal administration efficiently delivered mab a into male ps tauopathic mouse brain with target engagement and reduced tau pathology aggregation with little effect on total soluble tau further mab a treatment blocked apoptosis associated neuronal loss and brain atrophy reversed cognitive deficits and improved motor function in male tauopathic mice proteomic analysis revealed that mab a treatment reversed alterations mainly in proteins associated with synaptic functions observed in murine tauopathy and ad brain an antibody g targeting total tau also attenuated tau associated pathology and neurodegeneration but impaired the motor function of male tauopathic mice these results implicate p tau as a potential therapeutic target for ad associated neurodegeneration,False
33711510,,Therapy for Alzheimer's disease: Missing targets and functional markers?,33711510_0,the development of the next generation therapy for alzheimer s disease ad presents a huge challenge given the number of promising treatment candidates that failed in trials despite recent advancements in understanding of genetic pathophysiologic and clinical characteristics of the disease this review reflects some of the most current concepts and controversies in developing disease modifying and new symptomatic treatments it elaborates on recent changes in the ad research strategy for broadening drug targets and potentials of emerging non pharmacological treatment interventions established and novel biomarkers are discussed including emerging cerebrospinal fluid and plasma biomarkers reflecting tau pathology neuroinflammation and neurodegeneration these fluid biomarkers together with neuroimaging findings can provide innovative objective assessments of subtle changes in brain reflecting disease progression a particular emphasis is given to neurophysiological biomarkers which are well suited for evaluating the brain overall neural network integrity and function combination of multiple biomarkers including target engagement and outcome biomarkers will empower translational studies and facilitate successful development of effective therapies,False
38647399,,Hybrid Membrane-Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease.,38647399_0,the blood brain barrier bbb limits the application of most therapeutic drugs for neurological diseases nds hybrid cell membrane coated nanoparticles derived from different cell types can mimic the surface properties and functionalities of the source cells further enhancing their targeting precision and therapeutic efficacy neuroinflammation has been increasingly recognized as a critical factor in the pathogenesis of various nds especially alzheimer s disease ad in this study a novel cell membrane coating is designed by hybridizing the membrane from platelets and chemokine c c motif receptor ccr cells are overexpressed to cross the bbb and target neuroinflammatory lesions past unsuccessful endeavors in ad drug development underscore the challenge of achieving favorable outcomes when utilizing single mechanism drugs two drugs with different mechanisms of actions into liposomes are successfully loaded to realize multitargeting treatment in a transgenic mouse model for familial ad xfad the administration of these drug loaded hybrid cell membrane liposomes results in a significant reduction in amyloid plaque deposition neuroinflammation and cognitive impairments collectively the hybrid cell membrane coated nanomaterials offer new opportunities for precise drug delivery and disease specific targeting which represent a versatile platform for targeted therapy in ad,False
37700216,,Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets.,37700216_0,aging is a significant risk factor for alzheimer s disease ad although the precise mechanism and molecular basis of ad are not yet fully understood epigenetic mechanisms such as dna methylation and hydroxymethylation mitochondrial dna methylation histone modifications and non coding rnas ncrnas play a role in regulating gene expression related to neuron plasticity and integrity which are closely associated with learning and memory development this review describes the impact of dynamic and reversible epigenetic modifications and factors on memory and plasticity throughout life emphasizing their potential as target for therapeutic intervention in ad additionally we present insight from postmortem and animal studies on abnormal epigenetics regulation in ad as well as current strategies aiming at targeting these factors in the context of ad therapy,False
34824300,8617296,Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus.,34824300_0,quercetin has demonstrated antioxidant anti inflammatory hypoglycemic and hypolipidemic activities suggesting therapeutic potential against type diabetes mellitus t dm and alzheimer s disease ad in this study potential molecular targets of quercetin were first identified using the swiss target prediction platform and pathogenic targets of t dm and ad were identified using online mendelian inheritance in man omim disgenet ttd drugbank and genecards databases the targets shared among quercetin t dm and ad were used to establish a protein protein interaction ppi network top core genes and protein functional modules using mcode metascape was then used for gene ontology and kyoto encyclopedia of genes and genomes kegg pathway enrichment analysis a protein functional module with best score was obtained from the ppi network using cytohubba and high probability quercetin targets akt jun mapk tnf vegfa and egfr were confirmed by docking simulations molecular dynamics simulation was carried out according to the molecular docking results kegg pathway enrichment analysis suggested that the major shared mechanisms for t dm and ad include age rage signaling pathway in diabetic complications pathways in cancer and mapk signaling pathway the key pathway we speculate that quercetin may have therapeutic applications in t dm and ad by targeting mapk signaling providing a theoretical foundation for future clinical research,True
19368497,9459667,Therapeutic targets for Alzheimer's disease.,19368497_0,alzheimer s disease ad the most common form of degenerative dementia represents a tremendous unmet medical need although ad had already been described about years ago and despite enormous research efforts at present only few symptomatic treatment options exist for the more than million patients worldwide this situation might change as many targets for therapeutic intervention have been identified based on the in depth study of the pathology of the disease in model systems and humans and of its underlying genetics these targets are highlighted in the context of contemporary drug discovery for the identification of new therapies translation of recent discoveries into disease modifying therapies has not yet been accomplished the future will show whether the current drug discovery and development pipelines of pharmaceutical companies yield efficacious new medicines for ad,True
